in a randomized study with 234 previously untreated patients with multiple myeloma , 129 were treated with melphalan ( 8 mg/m2 perorally for four days ) and prednisone ( 40 mg/m2 perorally for seven days , both every four weeks ) and 105 with melphalan and prednisone at the same doses plus cyclophosphamide ( 600 mg/m2 intravenously every four weeks ) , meccnu ( 100 mg/m2 po every eight weeks ) , and vincristine ( mpccv , 0.6 mg/m2 iv every four weeks ) .
C0026764
multiple
C0025241
melphalan